top of page
bd40ddc088c10a27ae5fa51924c34ebc.jpg
a1d6937fda4b241478e040dd53a74a52.jpg
461313371e15e3127573decb0ec9e105.jpg
db7e538c43fa3feed07cf13030ebcfea.jpg
e3cb5e81422c13ce487eb189ad4033e1.jpg
b286da168cfc355a5176ef8e0653a224.jpg
d3eeb9a95c52beee45d2e0a1a1f171d5.jpg
aec7419175915e884aa96ea14049e4b4.jpg
96102654ea68326367caea7ab1dc5e4d.jpg
bee6f954019b7c1986740917f1b5dad7.jpg
8696041d12afaa8acc8b963406d422a8.jpg
25254fae6e9d62d0a31e0966a96e0c92.jpg
6270e67c61e905cd946df5ac29297a88.jpg

​

生きた皮膚を3D印刷 「シワはプリンターで除去」する未来

966978941034a79751188067c7947843.jpg
d06792b9765ed7f032927de3a06bf6fb.jpg
57f7622c51c0bf4bc21575eece3a5828.jpg
8fc826f11dee97a324d94c4b85f7f772.jpg
01125d773990af7e103bbf5cb7fef385.jpg
8659d4a99ed071b02822bf0d54032674.jpg
3f81997eacab2d0c8d3d4f9cc67d470e.jpg
6a5fd9bdff0709e0b98b6e6bf7d416f3 (1).jpg
Free_Sample_By_Wix (8).jpeg
designall.jpeg
aff257cd27e554c28b4c671218510088.jpg
787cb37dd23024f4523bf30957048acc.jpg
06abc74c6b6a68b46b2ce8162069fb71.jpg
6a5fd9bdff0709e0b98b6e6bf7d416f3.jpg
6d50e9896f4fc3064e1173b670578576.jpg
6da868670b4ee5f0edcaef9137a9cacd.jpg
8b50d366ac253f2ef0514a34f4a2b4f1.jpg
8fc826f11dee97a324d94c4b85f7f772 (1).jpg
e3cb5e81422c13ce487eb189ad4033e1.jpg
e86d30e839e10f849680cd4ccead1b05.jpg
e505c53cb6edc2e9e792971d4e472eab.jpg
f3cbd69c5db02f7fed59a3f2a1391bcb.jpg
30eb9c95b28f88bbb23c7c91a866d282.jpg
HOCITGROUP.png
fc40d16bd654de1719e2a9ab8765d679.jpg
f4fd4d1ccb6a16c70c239693ca980237.jpg
Congratulations on the first anniversary of the establishment of HOCIT in China and the establishment of HOCIT in Japan
a05d537707e21b44cc4898bd2b45c4da.jpg
d3196aaa037b1023a1cf6e503597fcd9.jpg
d1bce5b28aa95c73c8c8c30f09618fbf.jpg
dedd4af3118f746730823c102e259ae7.jpg
cfd7ffcfa3fa0ab95995b454192febd8.jpg
cdc56545bbd83e1956a79846edfeebd6.jpg
52a5a2b3bed299782027bb5b9f876098.jpg
7ff9c868d412a6e74650078a959c4aa4.jpg
5fd0b78a517d9b31115bb64397047b6e.jpg
4f2ac20cf58962c99ea2e35d12e2ffa9.jpg
4d09e085b2e6ea933eb340e5be5254d9.jpg
2a44d1c7b265dfa7655e96db20d81bda.jpg
04a671a4aa33f3e55fc71572a283a66d.jpg
f00309c2d7df272f2e4b6bc6a98c5a59.jpg
0ce9638751be256a5f61c1baaba93558.jpg
7a085c779cb6711553bb922db7cb2b54.jpg
6f94f5c28bb3da6342350f0685b2a750.jpg
d0b978ed714dbe0bce8fe0cc3c8cbe0a.jpg
63a9455991ad3d043fe99e26b50c5bc2.jpg
4238745dee855908d16947429b7bb96e.jpg
6c2bc21ed475ca00d91a7d12616e2a66.jpg
e3cb5e81422c13ce487eb189ad4033e1.jpg
111997ea7714972c9ac89cdadceaf5f9.jpg
00a919fe299976a84039ad2faea01ce1.jpg
0e733ee6633425d0de663474b283c224.jpg
06abc74c6b6a68b46b2ce8162069fb71.jpg
8dc9c27f9d965dc49c3a6ffac022720c.jpg
9e50c0762a83431c0ee2265685e5ddc9.jpg
34ce8f4ba2c1e311cfbab63a1f1af89d.jpg
8b2da8cc33a25f6803f49d5dd07a5bb0.jpg
8dc9c27f9d965dc49c3a6ffac022720c.jpg
31b11d5b1cc268bc5f07acc6809a1472.jpg
34ce8f4ba2c1e311cfbab63a1f1af89d.jpg
49f3e975fa4a593ac86f6a89a898bfe8.jpg
70e6822092a3938225aaf73881c31a61.jpg
71e1479658c2c15c30eb571bdd94c68c.jpg
78c72fa99bb7dcfdff732130e32edf0d.jpg
91a9ca8277f73d1ad5199b35c305b2eb.jpg
98d26d0f3bb463e70de13d4d7059df74.jpg
1280px-100_thieves_logo.svg.png
3598dc35a99ec341c4e70095989b258d.jpg
82322e8f956102ad2cd489273c94a46f.jpg
833ad4d227d1926e93e1662ebfd6b0ae.jpg
af318d1a8842d73114ddbd93e3134645.jpg
787cb37dd23024f4523bf30957048acc.jpg
578d76a5e9a94dfc8fdabe5a4f92fd3e.jpg
163b45684d3403c9a68eb79c7905ec58.jpg
459c1f5b9b666c5939a637fc650c9728.jpg
c08cc2c0ccea4127dd34138570292f81.jpg
977a6592aa6ece01d65d3772c864c4cd.jpg
82322e8f956102ad2cd489273c94a46f.jpg
395020e887d13882e6b92c52afd556af.jpg
72485701f33f440726e22a68ad063279.jpg
96897079fe1a58fbd56167c7ece045da.jpg
585927376aeb2f611077c17c0bee5867.jpg
a2f4335989e3864ce460d12d16a16a2a.jpg
a6cce6dbb7604296d2350c9a8f715887.jpg
a86c7730df5ed786a48ad3c5d156aca5.jpg
ae5ce88f9b5706ef19e713eaf695cc95.jpg
aff257cd27e554c28b4c671218510088.jpg
affeabf98a66b2aac541645994fd5f23.jpg
bf622e51fea770a298089bdd34a6fa2e.jpg
c78ab2204ed0ce36c8c3b3deb698a681.jpg
85f7830154795a4a2e6082aa2850b14b.jpg
111997ea7714972c9ac89cdadceaf5f9.jpg
977a6592aa6ece01d65d3772c864c4cd.jpg
75e1b9236db7d9aa26098d17a53f1afe.jpg
de0fceb9b8e07c530fecd4482e67b907.jpg
e15ce4007ccf39020a4e6c96e3135ab8.jpg
download.png
31b11d5b1cc268bc5f07acc6809a1472.jpg
9e50c0762a83431c0ee2265685e5ddc9.jpg
7ddd9d4e4dc785d2220b8d7d40595eec.jpg
dedd4af3118f746730823c102e259ae7.jpg
8b2da8cc33a25f6803f49d5dd07a5bb0.jpg
0b6d658711a2b97337fb7034211e25d4.jpg
f37f1036cc2da968ba1aa78c4ebd7ac8.jpg
cf3786eb20428d8df75193f13b0cf442.jpg
de149803965492bce86ad252eb1892b2.jpg
d3f52d217c6f24f531488275e2bf56e0.jpg
c345687ccacd196fbb943e1202351b24.jpg
bee6f954019b7c1986740917f1b5dad7.jpg
f00309c2d7df272f2e4b6bc6a98c5a59.jpg
461313371e15e3127573decb0ec9e105.jpg
88430c02670b912b544305b80dc00785.jpg
95f930a44c47941b6279e87b74fd3fe5.jpg
ffdb08288e960e235729be4ac15262d8.jpg
6a241e471e8280ea3962397938d1ad97.jpg
vintage_mickey_minnie_bathroom_mat-r70b6
2a1d4a8961d2b70e6f77f8638b799dad.jpg
6a241e471e8280ea3962397938d1ad97.jpg
0f9dfb937fb84f570a0487e18319f748.jpg
9a5d08ff4082e5b784c56a565907d668.jpg
8854e30d59b10cbe40943c1a112b0087.jpg
6701b25a327dbbba99ddde2d9d014b01.jpg
15047483f3cb05c224e94af53518d830.jpg
718831a82e37734237207eb1db66d1a6.jpg
490889dc10cde3bd70aa1628b0d0a06f.jpg
e80758b649c385a22979b6bc324817fb.jpg
ed6defa5451728cb96bb7718bc16281a.jpg
f11ef491bad3d4175e70cbf6c341d107.jpg
f43c4fae0c163019522181daf9366095.jpg
fb841813b37c2a327fb599c590f6331c.jpg
f779a1f43c71ebdd12c5dfe08ebd3b95.jpg
53dab56f34ec43dbcb3cf66922a9d122.jpg
99c5077ff50adc48dfe06595e0fbe487.jpg
f692cc073ff93bdb403a65865474a2b9.jpg
a3e070f808112b4e554ff6defa5a11f4.jpg
6421128df2bc59c2a63df30a5c9e88f4.jpg
738aa06f4c6065073e99cd70b34fa5e9.jpg
aa8f8e078778054bb6836a07606cdf8d.jpg
eee68829af8d768d7c8c786c13a2f759.jpg
HOCITGROUP.png
6b9db3630d006d0b8c54cbd2d7ab0d9d.jpg

Welcome to the entrance to the world of acupuncture
Acupuncturist: a profession that will not disappear in the AI ​​era
With the development of AI (artificial intelligence), many existing occupations are expected to disappear. It is said that artificial intelligence has gradually entered the high-level intellectual professional fields such as finance and legal affairs, and has begun to serve people.

But what about acupuncture?

Acupuncture is a delicate and special technique that cannot be easily replaced by computers or machines. It can only be done manually. We often hear about their physical conditions from patients, consider the cause of the current symptoms, and select appropriate treatment points from 361 acupoints (acupoints) for acupuncture. This is a complex and delicate technique. It is impossible for robots. Even if it is possible, it will not be controlled by practitioners.

On the contrary, since it is surrounded by digital devices every day, do you think it needs the warmth, softness and safety of human hands? Acupuncture is a technology that is expected to become more valuable in the future AI era.

The WHO (World Health Organization) has also certified the therapeutic effects of acupuncture. Acupuncture therapy is good at treating symptoms that are difficult to improve by Western medicine, pain that has not been diagnosed as "discomfort" (discomfort) according to the examination results, and pain that cannot be completely cured. It is understandable that in recent years, the upsurge of Oriental medicine is coming, and it is said that this is a very stressful society. There is a growing demand for acupuncturists who can understand and treat patients' pain.

In addition, acupuncturists are long-term participants of men and women. This is not hard work, so even after aging, you can use the skills and intuition accumulated according to your physical strength to stand in the field of treatment. This is a lifelong job, you can improve your skills while you work, and cultivate opportunities for success while reaping rewards.
 

ACCELERATE OUTCOMES WITH A BACKBONE FOR ARTIFICIAL INTELLIGENCE.

makes machine learning operational by connecting models to the real-world decisions they inform. Often, AI/ML algorithms live in experimental vacuums. Foundry provides the end-to-end infrastructure an organization needs to apply AI/ML to real problems and real data:

  • A data foundation.  provides the data engineering capabilities an organization needs to deploy AI/ML models it can trust. Organizations use  to build a solid foundation of sufficient, quality data, then bring that data into daily operations.

  • Production deployment infrastructure. revolutionizes the way organizations build and deploy AI/ML by combining a data foundation with end-to-end algorithm deployment infrastructure. Data scientists and engineers can customize, deploy, assess, and compare across homegrown, open-source, and third-party algorithms. All models are tightly integrated with end-to-end platform capabilities, ranging from feature curation and health checks to model management to inference/serving to outcome monitoring.

  • Faster feedback loops. AI/ML models rarely work on a "set it and forget it" basis.  integrates the full model lifecycle with end user actions and feedback, and with operational decisions and outcomes. This enables operationally oriented model monitoring, management, understanding, selection, and adjustment. The result is more adaptable and ambitious AI/ML, faster.

UNITE THE ORGANIZATION AROUND A SHARED ENVIRONMENT FOR MACHINE LEARNING.

The most effective AI/ML encodes and supercharges an organization's unique expertise. That requires uniting an organization's data scientists, decision-makers, and everyday employees in an environment for collaborating on AI/ML-powered operations.  collaboration infrastructure drives AI/ML that brings the organization together:

  • A unifying ontology. ontology translates an organization's complex data landscape into human-readable concepts. built models reflect how an organization views the world and unite data scientists, engineers, analysts, executives, and operational end users around a common semantic layer.

  • Granular security controls. lets organizations define granular access control policies at the integration stage, then propagates those policies intelligently across the system. Organizations can promote collaboration confidently with granular data security and transparent data governance.

  • Model templates.model templates empower low-code and no-code AI/ML so even non-technical users can use AI to accelerate and enrich their workflows.

MAXIMIZE IMPACT AND MINIMIZE RISK WITH A PLATFORM DESIGNED FOR RESPONSIBLE ENGINEERING.

Our approach to AI/ML in  reflects our foundational belief in augmenting human intelligence, not replacing it. We believe AI/ML algorithms are most effective when they empower humans to ask complex questions, interpret answers, and act on results. At public and private sector organizations around the world, driven AI/ML is accelerating human decision-making by:

  • Surfacing new leads in dark web, weapons trafficking, financial fraud, and drug trafficking investigations so investigators can identify persons of interest more quickly

  • Aggregating and correlating biomedical research data to streamline drug discovery

  • Processing entity resolution suggestions so analysts can focus on making assessments rather than manually sorting and tagging data

  • Analyzing massive-scale sensor data so that engineers can make better aircraft maintenance decisions

  • Rapidly generating simulations while allowing operators to tweak scenario variables, leading to better-informed decisions optimized for different variables (e.g., safety rating and production quantity)

I see our approach to ethical machine learning as being grounded in an appreciation for both the promise and limitations of human-computer collaboration. The promise of AI is in augmenting and enhancing human intelligence, expertise and experience. Think helping a aircraft mechanic make better, more accurate and more timely repairs – not automating the mechanic out of the picture.

— Anthony Bak, Co-Lead of Palantir's Machine Learning team, in an interview with CTOVision

Protecting privacy and preserving civil liberties is fundamental to our mission.ships with technical capabilities that enable ethical engineering and ethical machine learning, including data protection features such as granular access controls, data provenance and lineage tracking, data retention and deletion management, and audit logging.  also enables industry-leading monitoring and validation for AI models. Its flexible, configurable tools let organizations evaluate model bias, in terms of both the data used to train the model and model outcomes.

We recognize that technology alone can't fully mitigate the risks of machine bias. Our dedicated Privacy and Civil Liberties team works with our engineers and our customers to approach building and deploying AI/ML thoughtfully.

Acupuncture significantly reduces AI-associated arthralgias

Publish date: December 8, 2017

By 

Roxanne Nelson

 

 

 

REPORTING FROM SABCS 2017

SAN ANTONIO – Acupuncture significantly reduced joint pain that was associated with the use of aromatase inhibitors (AIs) in women with early breast cancer, according to new findings reported at the San Antonio Breast Cancer Symposium.

The randomized, phase 3 SWOG S1200 clinical trial found that, compared with sham acupuncture and a control group receiving no therapy, women receiving acupuncture reported significantly lower scores on the Brief Pain Inventory–Short Form (BPI).

“We have shown consistently, with multiple measures assessing pain and stiffness, that true acupuncture generated better outcomes than either control group in a large multicenter trial,” said lead author Dawn L. Hershman, MD, leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center. “Acupuncture provides a nonpharmacologic option that can improve symptoms and possibly increase AI adherence and subsequent breast cancer outcomes.”

AIs can reduce both early breast cancer recurrence and mortality. Dr. Hershman noted that these agents are effective in the adjuvant setting and for prevention “but we know that it doesn’t work if you don’t take it. Noncompliance is a major problem among women taking hormonal therapy.”

Noncompliance is multifactorial and one of the main reasons women discontinue their therapy early is because of arthralgias or joint discomfort. “We were interested in a nonpharmacologic intervention, to assess whether or not we could control these symptoms.”

Dr. Hershman pointed out acupuncture provides a safe and effective alternative for patients reluctant to take a prescription medication that can result in other side effects. “Identification of nonopioid options for pain control is a public health priority,” she said.

Acupuncture is a popular nonpharmacologic modality and widely used for a number of indications. Several single-institution studies have suggested that it may be useful for controlling AI-associated arthralgias, while other studies have not demonstrated a benefit.

In this trial, the authors evaluated the efficacy of acupuncture, compared with sham acupuncture or waitlist control, in the treatment of AI associated arthralgia in a large population of patients. The study was conducted at 11 centers.

The cohort comprised 226 postmenopausal women diagnosed with early-stage, hormone receptor–positive breast cancer who were receiving treatment with AIs. The primary endpoint was the decline in joint pain as measured by BPI-SF at 6 weeks, and to assess the duration of the effect, the women were followed for an additional 12 weeks.

Within this group, 110 were randomized to true acupuncture; 59 to sham acupuncture, and 57 to waitlist control (no treatment). Patients receiving true or sham acupuncture had sessions three times a week for 6 weeks followed by one session per week for 6 more weeks. Pain status was reported at baseline, during treatment, and then afterwards, using a variety of measurement tools including the BPI-SF, which is a self-administered 14-item questionnaire that evaluates pain severity on a 0-10 scale, and the impact of pain on activities of daily living.

At 6 weeks, the true acupuncture treatment arm reported significantly lower BPI worst pain scores than those in the sham acupuncture and the waitlist control arms. The mean BPI worst pain for the true acupuncture arm was 0.92 points lower than the sham acupuncture arm (P = .01) and 0.96 points lower than the waitlist control arm (P = .01). The proportion of patients experiencing a large reduction in BPI worst pain (greater than 2) was significantly greater in the true acupuncture arm, compared with the other groups: 58% versus 33% percent and 31%, respectively. The differences continued to remain statistically significant at 24 weeks, even though the treatment only continued for 12 weeks.

Associated adverse effects were minimal with true and sham acupuncture and limited to grade 1 bruising.

The cost of the 12-week intervention was about $1,250 or $65-$75 a session. “We feel that there is now sufficient evidence to support insurance coverage of acupuncture of AI arthralgia.”

In a discussion of the paper, Dr. Anne Partridge, from the Dana Farber Cancer Center, noted that it is imperative to seek new ways to improve outcomes in breast cancer, and AIs are contributing to that. However, she echoed the concern that nonadherence to treatment is a “tremendous problem” and hampers the clinical effectiveness of AI therapy.

The rate of discontinuation during the first year of therapy is 20% within the first year and up to 40% of patients do not take them daily. Both early discontinuation and nonadherence contribute to mortality.

Based on these results from the largest randomized controlled trial looking at acupuncture in this setting, should physicians be recommending acupuncture to patients prescribed AI therapy?

“The short answer is, why not?” said Dr. Partridge, “And that we should be recommending it for some of our patients.”

However, there are a number of issues that need to be addressed, she added. The duration of treatment is not known, and the need for follow-up treatment or the frequency of it is not known. The generalizability of it is also unclear when looking at a larger population, and acupuncture is highly operator dependent.

“There are cost and access issues, and insurance right now offers very limited coverage,” she said.

Importantly, Dr. Partridge emphasized, “We know that it will help symptoms, but will it improve adherence to AI?”

It may improve adherence for some patients, but “side effects are only one factor,” she said. “Adherence behavior is complicated. We need to figure out how to optimize these therapies in our patients.”

This study was supported by the National Institutes of Health National Center for Complementary and Integrative Health and the Office of Research on Women’s Health, and grants from the NIH/National Cancer Institute Division of Cancer Prevention. Dr. Hershman declared no conflicts of interest. Dr. Partridge had no disclosures.

empty-wheelchair-parked-in-hospital-pict
digitwin.png

Illumina, Chinese Children's Hospital to Launch Newborn Sequencing Study

Apr 23, 2019

 

| 

staff reporter

 

NEW YORK (GenomeWeb) – Illumina and the Children's Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospital's neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants, Illumina said this week.

According to Illumina, the researchers plan to enroll 200 patients and compare the diagnostic rate of rapid WGS with genetic diagnostic methods such as microarray analysis and gene panel sequencing.

The researchers will also compare the time it takes to reach a diagnosis, impact on the patient's prognosis, and turnaround time.

Illumina will provide the sequencing reagents and the Children's Hospital of Fudan University will conduct the testing and data analysis and also be responsible for reporting results and providing genetic consultations with family members.

The hospital is also a sponsor of the Newborn Genome Project, which is creating a genome database for newborns in China in order to develop better methods for detecting genetic diseases in newborns and to establish standards for neonatal genetic diseases.

UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

Dec 13, 2019

 

| 

staff reporter

 

NEW YORK – Researchers from the Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 

The researchers used Guardant Health's liquid biopsy assay and Bio-Rad Technologies' droplet digital PCR (ddPCR) testing to identify errors — including mutations in the HER2, ESR1 and AKT1 genes — in circulating tumor DNA (ctDNA) that had been shed into the patients' bloodstream. 

During a presentation this week at the San Antonio Breast Cancer Symposium (SABCS), Nicholas Turner, molecular oncology professor at the Institute of Cancer Research, explained that his team wanted to solve the issue of genotyping breast cancer tumors without having to perform multiple biopsies. Turner highlighted the need for prospective studies to assess the accuracy of ctDNA testing in routine practice and the potential of these tools to guide targeted therapy without requiring solid tissue testing. 

With funding from Stand Up To Cancer (a fundraising campaign from Cancer Research UK and Channel 4) Turner's team therefore launched an ongoing prospective study, called "plasmaMATCH," to examine the clinical utility of ctDNA for metastatic breast cancer detection. The group enrolled a total of 1,044 patients with advanced breast cancer who had either progressed on prior drug therapy or relapsed within a year after adjuvant chemotherapy. 

The researchers analyzed ctDNA in blood samples from patients using the Guardant360 sequencing-based assay and Bio-Rad's ddPCR as an orthogonal method. Patients with identified mutations could also enroll in a treatment arm of the study that matched their mutation. 

Turner and his team split the patient population into three major cohorts depending on specific genetic errors found in ctDNA: ESR1 mutations, HER2 mutations, and AKT-1 mutations in estrogen-receptor-positive breast cancer. The researchers also added a fourth cohort that had AKT-1 and PTEN mutations based on both ctDNA and tumor sequencing results, as well as a fifth group with triple-negative breast cancer without mutations. 

While Turner's team's initially aimed to measure the response rate of targeted therapies matched to mutations in ctDNA without tissue testing, the researchers also monitored the frequency of mutations, accuracy of testing, proportion of patients entering a treatment cohort, and the activity in clonality-dominant versus subclonal mutations. Turner's team discovered that 784 patients who had cfDNA testing done with both Guardant360 and ddPCR had "very strong agreement" of between 96 and 99 percent. Comparing the ctDNA to the patients' tumor samples to validate the plasmaMATCH findings, the researchers found that the liquid biopsy assay had an overall sensitivity of 93 percent. 

Guardant360 also identified several more targetable alterations than hotspot testing, including over 35 percent more PIK3CA mutations that can be targeted by US Food and Drug Administration-approved therapies. The assay also detected significantly more ESR1 mutations and found previously undetected microsatellite instability and ERBB2 mutations.   

The researchers provided 142 patients that had specific identified mutations experimental targeted therapies as part of the study, and they plan to test the treatments that showed initial promise in larger clinical trials. 

The researchers now believe that they can use blood testing to identify rare subtypes of breast cancer, in addition to potentially replacing more invasive methods of breast cancer detection. 

"We have now confirmed that blood tests can quickly give us a bigger picture of the mutations [that] are present within multiple tumors throughout the study," Turner said in a statement.  

"We show that circulating tumor DNA testing offers a simple, efficient, and fast method of tumor genotyping," Turner also noted during the presentation at SABCS. "The patients with mutations identified in their ctDNA have efficacy with matching target[ed] therapies." 

The researchers believe the blood-based assays are now reliable enough to be applied routinely by clinicians after receiving regulatory approval.

"As the number of treatment-relevant genomic alterations in metastatic breast cancer continues to grow, it is critical that oncologists have a simple and reliable way to comprehensively test for this information about their patients," Guardant Health Global Chief Medical Officer Rick Lanman said in a statement. "Guardant360 detected changes in the genome picture over time … and also identifies targetable but uncommon genomic biomarkers."

1c8b9b577cc41266ebab5e65ff8f3de8.jpg
090320_COVID_Test_0111-1024x682.jpg
05b50bc878af8f403a01848035fa3a86.jpg
7d54e3018152c4d0b389e55596039404.jpg
4deac0802d4054a8a85b3f3d256911aa.jpg
hocit999 - コピー_ページ_16.jpg
hocit999_ページ_6.jpg
bottom of page